Strategies to design clinical studies to identify predictive biomarkers in cancer research.

doi:10.1016/j.ctrv.2016.12.005

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Strategies to design clinical studies to identify predictive biomarkers in cancer research.

Cancer treatment reviews - 1 Feb 2017

Perez-Gracia Jose Luis, Sanmamed Miguel F, Bosch Ana, Patiño-Garcia Ana, Schalper Kurt A, Segura Victor, Bellmunt Joaquim, Tabernero Josep, Sweeney Christopher J, Choueiri Toni K, Martín Miguel, Fusco Juan Pablo, Rodriguez-Ruiz Maria Esperanza, Calvo Alfonso, Prior Celia, Paz-Ares Luis, Pio Ruben, Gonzalez-Billalabeitia Enrique, Gonzalez Hernandez Alvaro, Páez David, Piulats Jose María, Gurpide Alfonso, Andueza Mapi, de Velasco Guillermo, Pazo Roberto, Grande Enrique, Nicolas Pilar, Abad-Santos Francisco, Garcia-Donas Jesus, Castellano Daniel, Pajares María J, Suarez Cristina, Colomer Ramon, Montuenga Luis M, Melero Ignacio

Abstract excerpt

The discovery of reliable biomarkers to predict efficacy and toxicity of anticancer drugs remains one of the key challenges in cancer research. Despite its relevance, no efficient study designs to identify promising candidate biomarkers have been established. This has led to the proliferation of a myriad of exploratory studies using dissimilar strategies, most of which fail to identify any promising targets and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anaplastic Lymphoma Kinase

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Biomedical Research

Share to Clinical Trials as Topic

Share to Proto-Oncogene Proteins B-raf

Share to Proto-Oncogene Proteins c-kit

Share to ras Proteins

Share to Receptor, ErbB-2

Share to Receptor Protein-Tyrosine Kinases

Source

Open in PubMed

Identifiers

PMID: 28088073
DOI: 10.1016/j.ctrv.2016.12.005

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Strategies to design clinical studies to identify predictive biomarkers in cancer research.PMID 28088073Read ↗

Molecular-targeted anticancer therapy: challenges related to study design and choice of proper endpoints.Semantic proximity Read ↗

Considerations About the Use of Biomarkers in Cancer Clinical Trials.Semantic proximity Read ↗

Cancer molecular markers: A guide to cancer detection and management.Semantic proximity Read ↗

Critical comments for roles of biomarkers in the diagnosis and treatment of cancer.Semantic proximity Read ↗

Exploitation of Gene Expression and Cancer Biomarkers in Paving the Path to Era of Personalized MedicineSemantic proximity Read ↗

Clinical trial designs for prospective validation of biomarkers.Semantic proximity Read ↗

Molecular Mechanisms of Cancer Drug Resistance: Emerging Biomarkers and Promising Targets to Overcome Tumor ProgressionSemantic proximity Read ↗

Clinical Biomarkers in OncologySemantic proximity Read ↗

Statistical and practical considerations for clinical evaluation of predictive biomarkers.Semantic proximity Read ↗

Biomarker-Driven Early Clinical Trials in OncologySemantic proximity Read ↗

The Future of Cancer Diagnosis and Treatment: Unlocking the Power of Biomarkers and Personalized Molecular-Targeted TherapiesSemantic proximity Read ↗

Biomarker-driven patient selection for early clinical trialsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.